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BACKGROUND AND PURPOSEbph_920 885..898
Oxidative stress [i.e. increased levels of reactive oxygen species (ROS)] has been suggested as a pathomechanism of different
diseases, although the disease-relevant sources of ROS remain to be identiﬁed. One of these sources may be NADPH oxidases.
However, due to increasing concerns about the speciﬁcity of the compounds commonly used as NADPH oxidase inhibitors,
data obtained with these compounds may have to be re-interpreted.
EXPERIMENTAL APPROACH
We compared the pharmacological proﬁles of the commonly used NADPH oxidase inhibitors, diphenylene iodonium (DPI),
apocynin and 4-(2-amino-ethyl)-benzolsulphonyl-ﬂuoride (AEBSF), as well as the novel triazolo pyrimidine VAS3947. We used
several assays for detecting cellular and tissue ROS, as none of them is speciﬁc and artefact free.
KEY RESULTS
DPI abolished NADPH oxidase-mediated ROS formation, but also inhibited other ﬂavo-enzymes such as NO synthase (NOS)
and xanthine oxidase (XOD). Apocynin interfered with ROS detection and varied considerably in efﬁcacy and potency, as did
AEBSF. Conversely, the novel NADPH oxidase inhibitor, VAS3947, consistently inhibited NADPH oxidase activity in low
micromolar concentrations, and interfered neither with ROS detection nor with XOD or eNOS activities. VAS3947 attenuated
ROS formation in aortas of spontaneously hypertensive rats (SHRs), where NOS or XOD inhibitors were without effect.
CONCLUSIONS AND IMPLICATIONS
Our data suggest that triazolo pyrimidines such as VAS3947 are speciﬁc NADPH oxidase inhibitors, while DPI and apocynin
can no longer be recommended. Based on the effects of VAS3947, NADPH oxidases appear to be a major source of ROS in
aortas of SHRs.
Abbreviations
AEBSF, (4-2-amino-ethyl)-benzolsulphonyl-ﬂuoride hydrochloride; AUC, area under the curve; CAT, catalase; COLDER,
colour-developing reagent; DHE, dihydroethidium; DPI, diphenylene iodonium; eNOS, endothelial NOS; HBSS, Hanks’s
balanced salt solution; HUVEC, human umbilical vein endothelial cell; L-NAME, NG-nitro-L-arginine methyl ester;
NOX, NADPH oxidase; OPZ, opsonized zymosan; oxLDL, oxidized LDL; PBS, phosphate-buffered saline; PMA, phorbol
myristate acetate; ROS, reactive oxygen species; SHR, spontaneously hypertensive rat; SOD, superoxide dismutase;
VSMC, vascular smooth muscle cell; WCH, whole-cell homogenate; WKY, Wistar Kyoto (rats); XOD, xanthine oxidase
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Growing evidence suggests that an overproduction
of reactive oxygen species (ROS), such as superoxide,
hydrogen peroxide, hydroxyl radicals and peroxyni-
trite, contributes to the pathogenesis of cardiovascu-
lar diseases (Stocker and Keaney, 2004). With respect
to the relevant enzymatic sources of these ROS, the
family of NADPH oxidases has received considerable
attention (Griendling et al., 2000; Cave et al., 2006).
NADPH oxidases are comprised of membrane
proteins (i.e. the catalytic ﬂavin–heme protein);
NOX, of which ﬁve isoforms exist (NOX1–5); and
the non-catalytic 22 kDa binding protein, p22phox
(Lassegue and Clempus, 2003). Other components
of the NADPH oxidase complex can include a cyto-
solic organizer (p47phox or NOXO1), an activator
(p67phox or NOXA1) and other proteins (p40phox
and Rac). These cytosolic subunits vary with the
different NOX isoforms (Opitz et al., 2007). Upon
phosphorylation, cytosolic subunits translocate to
the NOX-containing membrane resulting in ROS
formation. However, NOX4 and NOX5 may be inde-
pendent of cytosolic subunits and constitutively
active (Brandes and Kreuzer, 2005; Bedard and
Krause, 2007; Lambeth et al., 2007; Opitz et al.,
2007) or regulated by intracellular free calcium
(Bedard and Krause, 2007) respectively.
The only known function of NADPH oxidases is
to generate ROS. This feature makes NADPH oxi-
dases distinct from other sources of ROS such as
xanthine oxidase (XOD) or uncoupled NOS as these
enzymes produce ROS only after conversion to a
dysfunctional state. This is triggered by ROS derived
from a primary source. NADPH oxidases may be this
primary source of ROS, initiating oxidative stress
and converting other enzymes into an ROS-
producing state (McNally et al., 2003) to eventually
induce cardiovascular pathophysiology. To test this
hypothesis, both genetic and pharmacological
approaches have been pursued.
According to studies using genetically modiﬁed
mice, NOX1 plays a role in the pathophysiology of
hypertension (Matsuno et al., 2005; Gavazzi et al.,
2006) and in neointima formation in mice (Lee
et al., 2009). However, pharmacological evidence –
and thus the potential of translating these ﬁndings
into therapeutic applications – has not yet been
provided. This is mainly due to the lack of speciﬁc
NADPH oxidase inhibitors. In particular, there are
concerns about the speciﬁcity of compounds cur-
rently used as NADPH oxidase inhibitors. For
example, one of the most frequently applied com-
pounds, apocynin, may also act as an antioxidant
(Heumuller et al., 2008) and a Rho kinase inhibitor
(Schluter et al., 2008). Other compounds that have
been widely used include 4-(2-aminoethyl)-
benzenesulphonyl ﬂuoride (AEBSF) (Bayraktutan,
2005), which blocks p47phox translocation to the
membrane but also inhibits serine proteases
(Diatchuk et al., 1997), as well as diphenylene iodo-
nium (DPI). DPI also inhibits other ﬂavin-
containing enzymes such as NOS and XOD
(O’Donnell et al., 1993), as well as cholinesterases
and the internal calcium pump (Tazzeo et al., 2009).
We here directly compared the speciﬁcity and
efﬁcacy of the most commonly investigated NADPH
oxidase inhibitors in three different cell lines, and
isolated enzyme preparations using several assays
for ROS detection. We also analysed the compounds
in situ in vascular tissue sections of spontaneously
hypertensive rats (SHRs). We are aware that many, if
not all, of the ROS assays have limitations with
respect to speciﬁcity and artefacts (Dikalov et al.,
2007). Therefore, we followed current recommenda-
tions and used several of the most frequently used
ROS detection systems in parallel to ensure that our
data are not only representative, but also compa-
rable to previous papers.
We included the triazolo pyrimidine VAS3947, a
novel derivative of VAS2870 with higher solubility.
VAS3947hasbeendevelopedbyinsilicooptimization
of VAS2870 (Tegtmeier et al., 2005), which was
recently shown to inhibit NADPH oxidase activity in
primary rat vascular smooth muscle cells (VSMCs)
(ten Freyhaus et al., 2006), and human umbilical
vein endothelial cells (HUVECs) (Stielow et al.,
2006). VAS2870 also inhibited wound margin H2O2
production without obvious toxicity in zebraﬁsh
larvae (Niethammer et al., 2009), as well as platelet-
derived growth factor (PDGF) BB-stimulated vascu-
logenesis of embryonic stem cell-derived endothelial
cells (Lange et al., 2009). We here show that, among
the tested compounds, only VAS3947 was an appar-
ently speciﬁc inhibitor of NADPH oxidases, which
did not interfere with commonly used ROS assays.
Using this novel inhibitor, we also provide pharma-
cological evidence that NADPH oxidases are indeed a
relevant source of ROS in the SHR model of hyper-
tension. Having established the speciﬁcity, future
experiments are justiﬁed to determine the mecha-
nism of action, the isoform speciﬁcity and the in vivo
actions of this novel NADPH oxidase inhibitor com-
pound class, which is beyond the scope of this study.
Methods
RNA isolation and RT-PCR
Total RNA was isolated from the human CaCo-2 and
HL60, and the rat A7r5 cell lines using the RNeasy
Kit (Qiagen, Hilden, Germany) and treated with
BJP
S Wind et al.
886 British Journal of Pharmacology (2010) 161 885–898DNase I (Invitrogen, Karlsruhe, Germany) according
to the manufacturers’ protocols. Total RNA was then
reverse transcribed by Superscript III using the pro-
tocol for random hexamer primers (Invitrogen).
Thereafter, each reaction was treated with RNase H
(Invitrogen) for 20 min at 37°C before PCR was per-
formed [94°C 5 min, 94°C 1 min–60°C 1 min–72°C
30 s (35¥), 72°C 10 min] using the following speciﬁc
primers: human NOX1 (5′-tctctccagcctatctcatg-3′,
5′-ctcattcatgctctcctctg-3′), NOX2 (5′-tcctccaccaa
aaccatccg-3′,5 ′-aaaaccgcaccaacctctcac-3′), human
NOX3 (5′-ctgccctgacagatgtatttc-3′,5 ′-gtcagtattttcg
tcccagtg-3′), human NOX4 (5′-tctggctctccatgaatgtc-
3′,5 ′-agaagttgagggcattcacc-3′), human NOX5 (5′-
gtgcatcatggaagtcaacc-3′,5 ′-ccaaaagtatctcagagccc-3′),
or rat NOX1 (5′-cctgctcattttgcaaccac-3′,5 ′-catgaga
accaaagccacag-3′), rat NOX2 (5′-gacagacttcggaca
gtttg-3′,5 ′-actctagcttggatacctgg-3′) and rat NOX4
(5′-gtgtttgagcagagcttctg-3′,5 ′-gtgaagagaagctttctggg-
3′). Puriﬁed PCR fragments were subcloned in
pCR2.1 TOPO (Invitrogen) and validated by
sequencing (GENterprise Gesellschaft für Genanal-
yse und Biotechnologie mbH, Mainz, Germany).
Cell culture
A7r5 cells (rat, smooth muscle embryonic aorta,
ATCC-No. CRL 1444) were cultured in Dulbecco’s
modiﬁed Eagle’s medium (Sigma, Deisenhofen,
Germany) supplemented with 0.1% glucose, 10%
heat-inactivated calf serum, 100 U·mL
-1 penicillin,
100 mg·mL
-1 streptomycin and 2 mM glutamine.
CaCo-2 cells (human, adenocarcinoma, colon,
ATCC-No. HTB 37) were cultured with medium of
the same composition as for A7r5 cells, but addi-
tionally supplemented with 1% non-essential
amino acids. Cells were cultured at 37°C under an
atmosphere of 6% CO2 until they reached 70–80%
conﬂuence. Cells were washed with phosphate-
buffered saline (PBS) buffer (2.7 mM KCl, 1.5 mM
KH2PO4, 137 mM NaCl, 8 mM Na2HPO4, pH 7.3)
and detached using a solution of trypsin (0.05%)
and EDTA (0.02%) in PBS buffer. Subsequently, cells
were counted and resuspended in reaction buffer
[140 mM NaCl, 5 mM KCl, 0.8 mM MgCl2 ¥ 2H2O,
1.8 mM CaCl2 ¥ 2H2O, 1 mM Na2HPO4,2 5 m M
HEPES, 0,1% (w/v) glucose, complete EDTA-free pro-
tease inhibitor cocktail; pH 7.3] to a concentration
of 2 ¥ 10
6 cells·mL
-1.
HL-60 cells (human, promyeloblast, ATCC-No.
CCL 240) were cultured in RPMI-1640 medium (PAA
Laboratories GmbH, Pasching, Austria) supple-
mented with 5% fetal calf serum, penicillin
(100 U·mL
-1), streptomycin (100 mg·mL
-1) and
glutamine (2 mM). Cell suspensions (5 ¥ 10
5
cells·mL
-1) were incubated with 1.25% DMSO for 6
days to induce differentiation into granulocyte-like
cells. Differentiated cells were centrifuged at 300¥ g,
washed with Hanks’s balanced salt solution (HBSS,
PAA Laboratories GmbH) and resuspended in HBSS
to a ﬁnal concentration of 4.4 ¥ 10
6 cells·mL
-1.
NADPH oxidase activity assay in cell
homogenates
In CaCo-2 and A7r5 whole-cell homogenates
(WCHs), NADPH oxidase-catalysed ROS formation
was measured using lucigenin-enhanced chemilu-
minescence according to the protocol of Li and
Shah (2001) with slight modiﬁcations. A7r5 and
CaCo-2 cells were suspended in reaction buffer (2 ¥
10
6 cells·mL
-1) and then underwent three freeze
(-20°C) thaw cycles to produce WCH. We routinely
conﬁrmed complete lysis of the cells under the
microscope. The chemiluminescent probe lucigenin
was added to WCH to a ﬁnal concentration of 5 mM.
Then, 100 mL aliquots of WCH (2 ¥ 10
5 cells equiva-
lent) were transferred to individual wells of an
opaque white 96-well plate. Inhibitors were directly
added to the wells in the speciﬁed concentrations,
and the reaction mixture was incubated for 30 min
at 37°C in the dark. Subsequently, the reaction was
started by the addition of 100 mM NADPH, and
chemiluminescence was recorded every 3 min over
a period of 9 min (CaCo-2) or 21 min (A7r5) in a
luminescence reader (Fluoroscan Ascent FL; Thermo
Labsystems, Vantaa, Finland). All measurements
were performed in duplicate and repeated at least
three times. Results are expressed as area under the
curve (AUC), normalized as either a percentage of
the NADPH-induced signal in untreated WCH or as
a percentage of the superoxide dismutase (SOD)
(250 U·mL
-1)/catalase (CAT) (1000 U·mL
-1) inhib-
itable control signal.
Whole-cell NADPH oxidase activity assay
During the oxidative burst stimulated by phorbol
myristate acetate (PMA) in HL-60 cells, NADPH
oxidase activity was measured using the superoxide-
speciﬁc chemiluminescent probe L012. L012 was
added to DMSO-differentiated HL-60 cell suspen-
sions to a ﬁnal concentration of 100 mM. At this
concentration, L012 is reportedly devoid of redox
cycling properties (Sohn et al., 1999). Then, 100 mL
aliquots of cell suspension (4.4 ¥ 10
5 cells) were
transferred to individual wells of a 96-well plate.
Inhibitors were directly added to the wells at the
speciﬁed concentrations. Following a 30 min incu-
bation at 37°C in the dark, the oxidative burst was
initiated by the addition of 100 nM PMA, and the
chemiluminescence signal was recorded every
5 min over a period of 60 min in the luminescence
reader mentioned above. All measurements were
performed in duplicate and repeated at least three
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a percentage of the signal generated by untreated
PMA-stimulated HL-60 cells.
A second series of experiments was performed in
which we used cytochrome c reduction as an alter-
native measure of superoxide production. Cyto-
chrome c was added to the DMSO-differentiated
HL-60 cell suspension to a ﬁnal concentration of
100 mM. Then, 100 mL aliquots (4.4 ¥ 10
5 cells) were
transferred to individual wells of a 96-well plate.
Following the direct addition of inhibitors, cells
were incubated for 30 min at 37°C in the dark. Sub-
sequently, the oxidative burst was initiated by the
addition of PMA (ﬁnal concentration 100 nM) and
the cells incubated for 120 min at 37°C. Absorbance
was then measured at 540 nm (isosbestic point of
cytochrome c) and 550 nm (SpectraMax 340;
Molecular Devices, Sunnyvale, CA, USA). Each
experiment was performed in duplicate and
repeated at least three times. Signals were calculated
by normalization of the signals obtained at 540 nm.
The blank signal (HBSS buffer, cytochrome c,P M A )
was subtracted and all values expressed relative to
the control signal (cells, cytochrome c, PMA).
Additional cytochrome c assays were performed
using opsonized zymosan (OPZ)-treated HL-60 cells
instead of PMA treated. OPZ was prepared from
zymosan A from Saccharomyces cerevisiae (Vejrazka
et al., 2005). Brieﬂy, 5 mg·mL
-1 zymosan A was incu-
bated with normal human serum for 30 min at
37°C. Finally, zymosan was washed and resus-
pended in HBSS; 500 mg·mL
-1 OPZ was used for
stimulation of oxidative burst.
In situ tissue ROS assay
All animal care and experimental procedures com-
plied with the recommendations of the Federation
of European Laboratory Animals Science Associa-
tion, and were approved by the local ethics commit-
tee. Rats (SHR and WKY) were bred in the animal
facilities of the Rudolf Buchheim Institute, Giessen,
and fed standard rodent chow and water ad libitum.
Thoracic aortas of 12- to 14-month-old SHRs (n = 6)
and WKY (n = 6) were embedded in Tissue Tek O.C.T.
Compound (Sakura Finetek, Torrance, CA, USA).
Unﬁxed frozen cross sections (5 mm) were incubated
with dihydroethidium (DHE) (5 mM; Invitrogen,
Darmstadt, Germany) in a light-protected moist
chamber at 37°C for 30 min. Before incubation with
DHE, serial sections were treated with either
L-NAME (100 mM), pegylated SOD (PEG-SOD)
(250 U·mL
-1), oxypurinol (100 mM) or VAS3947
(10 mM) for 30 min at 37°C. Images were obtained
with a DM 6000 B ﬂuorescence microscope (Leica,
Wetzlar, Germany) using the same imaging settings
for each sample. For semi-quantitative analysis of
ROS production, total ﬂuorescence intensity was
analysed with the FW4000 software (Leica) using
three to six images from three sections per aortic
ring for each experimental condition.
Xanthine/XOD activity assay
Xanthine (ﬁnal concentration: 500 mM) and cyto-
chrome c (ﬁnal concentration: 100 mM) were dis-
solved in HBSS, and 100 mL aliquots of this
solution were transferred to individual wells of a
96-well plate. After addition of the inhibitors, the
mixtures were allowed to equilibrate for 20 min.
The reaction was started by the addition of 100 mL
XOD (ﬁnal concentration: 20 mU·mL
-1), and absor-
bance at 540 and 550 nm was recorded 10 min
after the start of the reaction (SpectraMax 340;
Molecular Devices). Superoxide production was cal-
culated by normalization of the signals obtained at
540 nm. The blank signal (without xanthine) was
subtracted.
A L012-based xanthine/XOD assay was per-
formed with the same substances and concentra-
tions as mentioned above using 100 mM L012
instead of cytochrome c. After an equilibration time
of 20 min, the reaction was started with XOD
(20 mU·mL
-1), and the chemiluminescence was
recorded for 20 min in a Fluoroscan FL microplate
reader. Signals were calculated as AUC and related to
the xanthine/XOD-derived control signal.
Endothelial NOS (eNOS) activity assay
eNOS activity was determined in homogenates of
Sf9 cells (derived from Spodoptera frugiperda) trans-
fected with a recombinant baculoviral vector
expressing human eNOS (Schmidt et al., 1996; Frey
et al., 1999). A colorimetric 96-well microtiter plate
assay for the determination of enzymatically
formed citrulline was performed according to the
method of Knipp and Vasak (2000) with slight
modiﬁcations. Brieﬂy, 90 mL reaction mixture
pH 7.5 (100 mM Tris–HCl, 0.05 mM calmodulin,
1 mM CaCl2,1 mM ﬂavin adenine dinucleotide,
1 mM ﬂavin mononucleotide, 250 mM CHAPSO,
1m ML-arginine, 5 mM tetrahydrobiopterin, 1 mM
NADPH, 2 mM reduced glutathione) was incubated
with the speciﬁed concentration of NADPH
oxidase inhibitors (or the respective solvents) and
5 mL of eNOS cell homogenate for 60 min at 37°C.
The reaction was stopped by the addition of
300 mL colour-developing reagent (COLDER), con-
sisting of one part solution A (80 mM diacetyl-
monoxime, 2 mM thiosemicarbazide) and three
parts solution B [3 M H3PO4,6 MH 2SO4,2 m M
NH4Fe(SO4)2]. The mixture was heated for 15 min
at 95°C, cooled to room temperature and centri-
fuged for 5 min at 16 000¥ g. Then, 300 mL of each
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plate, and the absorption at 540 nm was recorded
(SpectraMax 340; Molecular Devices). A citrulline
calibration curve was performed by mixing 100 mL
of 0, 3.125, 6.25, 12.5, 25, 50, 100, 200 or 400 mM
citrulline in 100 mM Tris buffer containing 2 mM
reduced glutathione with 300 mL COLDER solu-
tion, and subsequently treated as described above.
Enzyme activity was calculated using the citrulline
calibration curve. The effects of NADPH oxidase
inhibitors were expressed as a percentage of the
respective control solutions. Signal inhibition by
L-NAME (1 mM) demonstrated speciﬁcity of the
assay for NOS. Standards were measured in dupli-
cate, while all other measurements were performed
in triplicate and repeated at least twice.
Data analysis
Data analysis was performed using Prism 4.0 for
Macintosh (GraphPad Software, San Diego, CA,
USA). IC50 values of concentration-dependent inhi-
bition curves were calculated with a non-linear
regression analysis using an algorithm for sigmoi-
dal dose–response with variable slopes. Results are
expressed as mean  SEM. Statistical differences
between the means were analysed by one-way
ANOVA followed by Bonferroni’s multiple range
test. A value of P < 0.05 was considered to be
signiﬁcant.
Materials
N,N-dimethyl-9,9–biacridinium dinitrate (lucige-
nin), cytochrome c from horse heart, N
G-nitro-L-
arginine methyl ester (L-NAME), oxypurinol, SOD
from bovine erythrocytes, CAT from bovine liver,
PMA, DPI chloride (dissolved in DMSO; 0.3–10 mM)
were purchased from Sigma (Deisenhofen,
Germany); 8-amino-5-chloro-7-phenylpyrido[3,4-
d]pyridazine-1,4-(2H,3H) dione (L012) from Wako
(Osaka, Japan); XOD from cow’s milk and complete
EDTA-free protease inhibitor cocktail from Roche
(Mannheim, Germany); 4′-hydroxy-3′-methoxya
cetophenone (apocynin) from Calbiochem (Darms-
tadt, Germany; in 40% ethanol, 3–1000 mM); AEBSF
from Merck (Darmstadt, Germany; in HBSS,
3–1000 mM); 3-benzyl-7-(2-oxazolyl)thio-1,2,3-
triazolo[4,5-d]pyrimidine (VAS3947) from Vasop-
harm GmbH (Würzburg, Germany; in DMSO).
Synthesis and analytical data for VAS3947 have been
described by Tegtmeier et al. (2005). The structure of
VAS3947 is shown in Figure 1. Solvent controls were
performed for all assays and did not have any sig-
niﬁcant effect, if not stated otherwise.
Results
CaCo-2, HL-60 and A7r5 cells collectively
express all known NOX subunits
First, we wanted to establish cell models that
physiologically expressed different NOX isoforms.
Therefore, we analysed the NOX mRNA expression
patterns using non-quantitative RT-PCR
(Figure 2A). In contrast to previous reports, our
batch of CaCo-2 cells not only expressed NOX1
mRNA, the predominant isoform in colon
(Rokutan et al., 2006), but also mRNAs of NOX2,
NOX4 and NOX5. As reported, HL-60 cells mainly
expressed NOX2 mRNA (Teufelhofer et al., 2003),
the main isoform in human neutrophils (Babior
et al., 2002). However, we also detected NOX5 in
these cells. Finally, A7r5 cells contained not only
NOX4 mRNA, the predominant isoform in VSMCs
(Wingler et al., 2001), but also NOX3, previously
thought to be conﬁned to the inner ear (Banﬁ
et al., 2004) and NOX1 (Suh et al., 1999). Thus,
none of the cell lines was speciﬁc for any NOX
isoform, and they expressed different NOX isoform
patterns. Jointly, the chosen cell lines expressed all
NOX isoforms relevant to the cardiovascular
system under basal conditions (i.e. NOX1, NOX2,
NOX4 and human NOX5).
Cellular ROS formation is independent of
XOD and NOS
We next characterized the likely enzymatic source
and nature of ROS generated in our chosen cell
models. The NADPH-dependent lucigenin (5 mM)
chemiluminescence in homogenates represents a
frequently used cell-free NADPH oxidase assay. At
that low concentration, lucigenin is claimed to be
free of relevant redox cycling and artefactual signals
(Munzel et al., 2002). Using this assay, we found that
Figure 1
Chemical structure of VAS3947 [3-benzyl-7-(2-oxazolyl)thio-1,2,3-
triazolo[4,5-d]pyrimidine]. VAS3947 was characterized by NMR and
mass spectrometry [
1H nmr (DMSO-D6): d 5.90 (s, 2H, CH2), 7.3–7.4
(m, 5H, Ph), 7.6 (s, 1H, Ar), 8.55 (s, 1H, Ar), 8.95 (s, 1H, H-5). ms:
(+APCI) m/z 311 [M+H]
+).
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and A7r5 cell homogenates (Figure 2B,D), and we
observed an additive effect when combining SOD
and CAT. Inhibition of the lucigenin signals by CAT
(Rost et al., 1998; Janiszewski et al., 2002), in the
absence and presence of SOD, suggested that lucige-
nin is also sensitive to H2O2 (Rost et al., 1998). Both
species, superoxide and H2O2, may originate from
NADPH oxidases (Cai, 2005). Therefore, the SOD/
CAT inhibitable fraction of the CaCo-2 and A7r5
signal was utilized as basal ROS formation. Never-
theless, the inhibition by SOD and CAT was not
complete. Although we made sure that all cells were
lysed, some cell organelles or intracellular vesicles
may stay intact under our lysis protocol. NADPH
oxidases and ROS can be highly localized, and SOD
Figure 2
NOX expression and NADPH oxidase activity in three different cell lines. (A) Reverse transcriptase PCR of the ﬁve human (NOX1–5) and four rodent
(NOX1–4) NOX isoform mRNAs in the human colon epithelial cell line CaCo-2, the human leucoblast cell line HL-60 and the rat aortic smooth
muscle cell line A7r5. All cell lines expressed more than one NOX subunit. For measurement of NADPH oxidase activity, CaCo-2
homogenates + substrate NADPH (B), PMA-treated HL-60 cells (C and E) and A7r5 homogenates + substrate NADPH (D) were incubated in the
absence or presence of SOD (250 U·mL
-1), CAT (1000 U·mL-1), oxypurinol (100 mM) or L-NAME (100 mM). ROS formation was measured by
lucigenin (B and D), or L012 (B) chemiluminescence, or by cytochrome c reduction (E). In none of the cells, detectable ROS formation originated
from NOS (inhibited by L-NAME) or XOD (inhibited by oxypurinol). Only in HL-60 cells, the assay signals were fully inhibited by SOD and thus
due to superoxide. In CaCo-2 and A7r5 cell homogenates, even the combination of SOD and CAT only partially attenuated the assay signal,
suggesting that only a fraction was due to superoxide and/or H2O2. In later experiments, only the SOD/CAT-inhibited signal component was
considered as a measure of superoxide/H2O2 formation in CaCo-2 and A7r5 cell homogenates. Data labelled ‘blank’ represent signals in the
absence of cells or homogenate. Values represent means  SEM of n  6 observations; ***P < 0.001, signiﬁcantly different from control values.
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explain these observations.
In PMA-stimulated HL-60 cells, the oxidative
burst was measured by L012-mediated chemilumi-
nescence (Figure 2C) (Daiber et al., 2004) and cyto-
chrome c reduction (Figure 2E). SOD completely
abolished the PMA-stimulated signal in both assays,
conﬁrming that superoxide is the only detectable
ROS released from PMA-stimulated HL-60 cells.
Consequently, the entire L012 signal was taken as
PMA-stimulated ROS formation in HL-60 cells.
To determine the enzymatic source of ROS, ROS
formation was re-assessed in the absence or presence
of the NOS inhibitor, L-NAME, and the XOD inhibi-
tor, oxypurinol. Both compounds failed to attenuate
the ROS signals in any of the assays, suggesting that
neither XOD nor uncoupled NOS are relevant
sources of ROS in our cell models under the condi-
tions used.
Antioxidant effects
NOX inhibitors may also reduce ROS signals by
direct antioxidant effects (i.e. radical scavenging).
Therefore, we performed a xanthine/XOD cyto-
chrome c reduction assay, which generates superox-
ide independent of NADPH oxidase activity. As
shown in Figure 3A, DPI and oxypurinol, but none
of the other compounds, potently attenuated the
XOD signal, suggesting a direct inhibition of XOD.
This is consistent with DPI being a ﬂavoprotein
inhibitor (Lange et al., 2009) as both NOX and XOD
are ﬂavoproteins. Interestingly, when using L012 to
detect ROS from xanthine/XOD, apocynin potently
interfered with the signal (Figure 3B). This conﬁrms
recent reports that apocynin directly scavenges reac-
tion products of H2O2, which are detected by L012,
but not by cytochrome c (Heumuller et al., 2008).
Surprisingly, AEBSF increased the L012 signal more
than eightfold, suggesting a previously unrecog-
nized interaction between L012 and AEBSF. This
may be particularly problematic when AEBSF is used
in homogenizing buffers as a serine protease inhibi-
tor (Kobayashi et al., 2007; Baumer et al., 2008).
VAS3947 (30 mM) was the only compound that did
not interfere with xanthine/XOD-derived L012
signals, suggesting this compound is free of antioxi-
dant or scavenging effects relevant to ROS detection.
Inhibition of non-NOX ﬂavoproteins
In addition to XOD, eNOS was used as a ﬂavopro-
tein control to test the speciﬁcities of NADPH
oxidase inhibitors. eNOS, like the catalytic NOX
subunit, binds NADPH and contains both a ﬂavin
and haem cofactor. As expected, DPI (10 mM) also
abolished eNOS activity (Figure 3C), while apocynin
(1 mM), AEBSF (1 mM) and VAS3947 (10 mM) had
Figure 3
Effect of the NADPH oxidase inhibitors apocynin (1 mM), AEBSF
(1 mM), DPI (10 mM) and VAS3947 on the activity of the ﬂavo-
protein XOD (30 mM VAS3947), and the ﬂavo-haem protein, eNOS
(10 mM VAS3947). XOD activity was assayed by cytochrome c reduc-
tion (A) or L012 chemiluminescence (B); eNOS activity was deter-
mined by L-arginine to L-citrulline conversion using recombinantly
expressed eNOS (C). SOD (250 U·mL
-1) and oxypurinol (1 mM)
served as positive controls for XOD activity and L-NAME (1 mM) for
eNOS activity. While apocynin did not scavenge superoxide in the
cytochrome c reduction assay, it interfered with the L012 chemilu-
minescence assay. DPI inhibited both XOD and eNOS, and was thus
no longer considered for NADPH oxidase enzyme assays in the
present study. Values represent means  SEM of n  5 experiments.
***P < 0.001, signiﬁcantly different from control values.
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activity in concentrations similar to those needed
for NADPH oxidase inhibition, it was no longer con-
sidered for further NADPH oxidase enzyme assays in
the present study. We also tested higher concentra-
tions (up to 100 mM) of VAS3947, and neither found
an effect on XOD nor on eNOS activity (not shown).
Concentration dependence and efﬁcacy
We next investigated the concentration dependence
and efﬁcacy of the remaining compounds, apocy-
nin, AEBSF and VAS3947. In CaCo-2 cell homoge-
nates, VAS3947 completely blocked NADPH-
dependent ROS production with an IC50 of 12 mM,
whereas apocynin and AEBSF caused only modest
inhibition (Figure 4A). In contrast, the L012 chemi-
luminescence signal from HL-60 cells was inhibited
by all three compounds (Figure 4B). The IC50 values
for apocynin and VAS3947 were 97 and 2 mM respec-
tively. Surprisingly, AEBSF exerted a biphasic
response with concentrations <300 mM increasing
the signal (EC50 = 30 mM) and higher concentrations
being inhibitory (IC50 = 0.42 mM). Considering the
increased signal in the L012 xanthine/XOD assay in
the presence of AEBSF (Figure 3B), a direct interac-
tion between AEBSF and L012 is likely. Because apo-
cynin exerted non-speciﬁc effects in the L012
xanthine/XOD assay, we hypothesized that the
inhibition seen in this HL-60 cell assay may not
necessarily be due to inhibition of NADPH oxidases.
Indeed, when using cytochrome c as a detection
reagent in HL-60 cells (Figure 4B), apocynin had
only a minor effect, while VAS3947 still completely
inhibited with a similar IC50 value (1 mM) as
observed in the L012 assay. In contrast to the L012
assay, AEBSF inhibited the cytochrome c reduction
signal in a monophasic manner and had a high IC50
value of 0.3 mM similar to the second inhibitory
phase with L012 (0.42 mM; see above).
We hypothesized that apocynin was insufﬁ-
ciently metabolized by PMA-stimulated HL-60 cells
and thus did not inhibit cytochrome c reduction
mediated by these cells. Previous observations
suggest that apocynin may be a pro-drug requiring
activation by myeloperoxidases (Heumuller et al.,
2008). Therefore, HL-60 cells were stimulated with
OPZ, which, in contrast to PMA, activates not only
NADPH oxidases, but also myeloperoxidase. Indeed,
under these conditions, apocynin attenuated cyto-
chrome c reduction (data not shown). VAS3947 and
AEBSF were as effective in OPZ as in PMA-treated
HL-60 cells (data not shown). In summary, VAS3947
was the only compound to effectively and consis-
tently inhibit the oxidative burst signal in HL-60
cells independent of the stimulus and the read-out
reagent.
Results obtained with homogenates of the third
cell line, A7r5, were similar to those obtained with
CaCo-2 cell homogenates when using the same
lucigenin assay. Apocynin and AEBSF partially, and
VAS3947 fully attenuated the NADPH-stimulated
signal (Figure 4D). The IC50 values calculated from
the concentration–response curves suggested milli-
molar potency for apocynin (1.9 mM) and AEBSF
(1.2 mM), and micromolar potency for VAS3947
(13 mM). Thus, VAS3947 also inhibits NADPH
oxidase in a vascular cell line mainly expressing
NOX4 and NOX3, whereas apocynin and AEBSF
were only weak inhibitors in this model with IC50
values approximately 100 times that for VAS3947.
NADPH oxidases are the main source of ROS
in the SHR aorta
Having established that apocynin and AEBSF have
considerably different IC50 values and are ineffective
in some NOX model systems, whereas VAS3947 con-
sistently inhibited NADPH oxidase activity in all
three cell lines with similar IC50 values, we consid-
ered VAS3947 as the most reliable NADPH inhibitor.
VAS3947 was therefore used as a pharmacological
tool to investigate the source of ROS in aortas of
aged SHRs (Figure 5), an established model of hyper-
tension and cardiovascular oxidative stress. The in
situ DHE stain is not speciﬁc for any ROS and
rather summarizes superoxide-, peroxide- and
peroxynitrite-mediated oxidative chemistry. This
DHE stain of SHR aortas was signiﬁcantly higher
throughout the aortic wall compared to the signal in
aortas from WKY control rats. Furthermore, it was
blocked by PEG-SOD and was resistant to both
L-NAME and oxypurinol. This suggested that super-
oxide was a major product leading to DHE oxida-
tion, and that it was neither derived from eNOS nor
XOD. Importantly, VAS3947 effectively inhibited
DHE-detectable ROS formation in SHR aortas, sug-
gesting that NADPH oxidases are a relevant enzy-
matic source of ROS throughout the aortic wall of
aged SHRs.
Discussion
In the present study, we established the comparative
pharmacology of the most frequently used and
novel NADPH oxidase inhibitors, applying some of
the most commonly used ROS assays. Of all inhibi-
tors investigated, the novel triazolo pyrimidine,
VAS3947, was the only compound that neither
interfered with the ﬂavoprotein, XOD, or the ﬂavo-
haem protein, eNOS, had no signiﬁcant antioxidant
activity, nor interfered with any of the ROS detec-
tion assays. Rather, VAS3947 effectively inhibited
BJP
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Figure 4
Maximal inhibition and potency of apocynin, AEBSF and VAS3947 to inhibit NADPH oxidase activity. Activity was measured in CaCo-2 (A) or A7r5
(D) cell homogenates as NADPH-induced and SOD/CAT-inhibitable lucigenin-derived chemiluminescence, or in DMSO-differentiated HL-60 cells
as measured by L012-derived chemiluminescence (B) or cytochrome c reduction (C). The left panels depict maximal inhibition; the right panels
concentration–response curves. Concentrations used for maximal inhibition were in CaCo-2 cell homogenates 1 mM apocynin, 1 mM AEBSF and
30 mM VAS3947 (A); in HL-60 cell-mediated L012 chemiluminescence 1 mM apocynin, 100 mM AEBSF and 10 mM VAS3947 (B); in HL-60
cell-mediated cytochrome c reduction 1 mM apocynin, 1 mM AEBSF and 10 mM VAS3947 (C); and in A7r5 cell homogenates 1 mM apocynin,
1 mM AEBSF and 30 mM VAS3947 (D). IC50 values for VAS3947 were 12 mM( A ) ,2mM( B ) ,1mM( C )a n d1 3mM (D). Apocynin had a potency in
the micromolar range (97 mM) only in the HL-60/L012 assay (B). AEBSF had the lowest potency (420 mMi nB ,3 0 4mMi nC ;1 . 2m Mi nD ) ,a n d
in the HL-60/L012 assay it even enhanced signal intensity at low micromolar concentrations (EC50 = 30 mM). Values represent means  SEM of
n  5 experiments. *P < 0.05, ***P < 0.001, signiﬁcantly different from control values.
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Effect of the NADPH oxidase inhibitors on ROS formation in aortic sections from 12- to 14-month-old SHRs as determined by in situ DHE tissue
stain. DHE signals are enhanced in SHR versus WKY rat aorta, and correlate with enhanced levels of NOX1, 2 and 4. Sections were incubated either
in the absence (Con) or presence of L-NAME (100 mM), PEG-SOD (250 U·mL
-1), oxypurinol (100 mM) or VAS3947 (10 mM). Signal intensity was
quantiﬁed and expressed as mean  SEM of three experiments (n = 6). **P < 0.01, signiﬁcantly different from control (CON).
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expressing different patterns of all known NOX iso-
forms. Therefore, at least in vitro, triazolo pyrim-
idines are new pharmacological tools for inhibiting
NADPH oxidases. Applying this novel tool, we
were able to establish that NADPH oxidases are a
major source of ROS in aortas of aged hypertensive
rats.
Based on genetic and other data, NADPH oxi-
dases potentially play a major role in the develop-
ment and progression of cardiovascular diseases
(Williams and Griendling, 2007). This would
suggest that it might be beneﬁcial to therapeutically
target NADPH oxidases. Apart from genetic mouse
models, pharmacological agents are essential to
provide proof-of-principle in non-mouse species
and to serve as experimental therapeutics. The ﬁrst
triazolo pyrimidine described as an NADPH oxidase
inhibitor was VAS2870, stemming from a systematic
compound screen in HL-60 cells. VAS2870 inhibits
NADPH oxidase activity in oxLDL-exposed HUVEC
(Stielow et al., 2006) and PDGF-stimulated primary
rat aortic VSMC (ten Freyhaus et al., 2006). VAS2870
also inhibits the stimulation of vasculogenesis of
mouse embryonic stem cells upon treatment with
PDGF-BB (Lange et al., 2009), and it inhibits wound
margin H2O2 production without obvious toxicity in
zebraﬁsh larvae (Niethammer et al., 2009). In addi-
tion, VAS2870 does not interact with ROS in an
antioxidant manner nor does it interfere with XOD
(ten Freyhaus et al., 2006). However, a major disad-
vantage of VAS2870 is its poor solubility. Therefore,
a closely related derivative, VAS3947, was developed
with an approximately four times better solubility
(data not shown). Apart from the solubility,
VAS3947 has strikingly similar properties compared
to VAS2870. For example, the IC50 values for NADPH
oxidase activity of PMA-stimulated HL-60 cells,
PMA-stimulated whole blood and freshly isolated
human lymphocytes stimulated with PMA are
essentially the same for both compounds (unpub-
lished data). VAS3947 (this study) and VAS2870 (not
shown) both effectively inhibit ROS production in
aortas of SHRs as assessed by in situ DHE staining.
Taken together, our evidence shows that: (i) the
potential to inhibit NADPH oxidases is a class effect
of triazolo pyrimidines; and (ii) this compound class
inhibits NADPH oxidase activity in a variety of cell
types and tissues of phagocytic, as well as non-
phagocytic, origin with similar efﬁcacy.
Our emphasis was to characterize the com-
pounds in the most commonly used assays. We have
therefore used alternative ways to characterize
NADPH oxidase inhibitors: PMA-stimulated ROS
release from HL-60 cells and NADPH-stimulated
ROS production in cell homogenates. For detection,
we used cytochrome c, L012 and lucigenin. We are
aware that these assays do have drawbacks.
Lucigenin-enhanced chemiluminescence has been
widely used and is reported to be reasonably speciﬁc
for superoxide. The lack of complete inhibition of
the lucigenin signal by SOD that we observed was
also reported by others (Rost et al., 1998). This indi-
cates that it is not completely speciﬁc for superox-
ide. Lucigenin can penetrate cells and is prone to
redox cycling. However, when 5 mM is used, the
amount of artefact is probably insigniﬁcant (Dikalov
et al., 2007). Compared to lucigenin, L012 is more
sensitive for the detection of ROS (Daiber et al.,
2004). H2O2 does not signiﬁcantly contribute to
L012-enhanced chemiluminescence. However, in
addition to reacting with superoxide, L012 also
detects peroxynitrite (Daiber et al., 2004). In con-
trast to lucigenin, L012 only detects extracellular
ROS, as does cytochrome c, which considered as a
‘gold standard’ for detection of superoxide released
in large amounts, such as during the respiratory
burst of neutrophils. A disadvantage is its poor sen-
sitivity (Dikalov et al., 2007).
In comparison to VAS3947, DPI is a less suitable
pharmacological tool to validate the involvement of
NADPH oxidase because of its effects on other ﬂavo-
enzymes, such as XOD and eNOS, as well as on
cholinesterases and the internal calcium pump
(Tazzeo et al., 2009). In our hands, apocynin had
only minor efﬁcacy and potency. This may in part
be due to the fact that apocynin is a pro-drug requir-
ing metabolic activation by myeloperoxidases. Fur-
thermore, in PMA-stimulated HL-60 cells, the
inhibition of the L012 signal by apocynin was
caused by interference with the assay, either due to
antioxidative effects or a direct interaction with
L012. Thus, inhibitory effects of apocynin in the
L012 assay may not necessarily reﬂect inhibition of
NADPH oxidase activity (Heumuller et al., 2008).
Interestingly, upon oxidation of apocynin during its
activation, the resulting apocynin radical becomes a
potent pro-oxidant with high capacity to oxidize
thiols and NADPH. The depletion of NADPH poten-
tially reduces NADPH oxidase activity (Castor et al.,
2010). AEBSF was a similarly weak NADPH oxidase
inhibitor in CaCo-2 and A7r5 cell homogenates,
possibly indicating an only minor role for p47phox-
dependent NADPH oxidases in these cells. Indeed,
NOXO1 and/or NOXA1, homologues of p47phox
and p67phox, may be of more relevance in CaCo-2
cells and not affected by AEBSF (Banﬁ et al., 2003;
Takeya et al., 2003). In NADPH-stimulated homoge-
nates from A7r5 cells, NOX4 may be the main
source of ROS and independent of cytosolic sub-
units. While AEBSF attenuated the oxidative burst of
HL-60 cells at high concentrations in the L012 and
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use this compound as an NADPH oxidase inhibitor
because it obviously interferes with L012 and has
off-target effects such as serine protease inhibition
(Diatchuk et al., 1997).
The mechanism of action of triazolo pyrimidines
such as VAS3947 and VAS2870 is unclear. In human
leucocytes, VAS2870 does not inhibit translocation
of p47phox to the membrane (ten Freyhaus et al.,
2006), but may still interfere with oxidase assembly
once the translocation has occurred. This assump-
tion is supported by experiments showing that
VAS2870 inhibits NOX2 activity in a cell-free system
when added before (ten Freyhaus et al., 2006), but
not after complex formation and stimulation of the
oxidase (unpublished observations). The consistent
potency and efﬁcacy of VAS3947 in different cell
and tissue models indicate that VAS3947, in contrast
to apocynin, is not a pro-drug.
VAS3947 effectively suppressed the DHE signal in
aortas of aged SHRs, suggesting that NADPH oxi-
dases are indeed a major source of ROS in this
disease model and that these enzymes can be phar-
macologically targeted. However, the pharmacoki-
netic proﬁle of VAS3947 and the in vivo efﬁcacy, as
well as long-term effects of NADPH oxidase inhibi-
tion, are unknown. In this context, peptide-based
NADPH oxidase inhibitors are more advanced. The
NOX2 homologous fusion peptide, gp91ds-tat (Rey
et al., 2001), which interferes with cytosolic subunit
translocation and activation of NOX2, inhibits
angiotensin II-induced aortic superoxide produc-
tion and hypertension in vivo (Rey et al., 2001). In
addition, adenoviral expression of this peptide
sequence in blood vessel adventitia had a beneﬁcial
effect, preventing neointimal hyperplasia (Dourron
et al., 2005). Because our focus was on small syn-
thetic molecules, and not on peptides, we did not
include gp91ds-tat in our study. Nevertheless,
NOX1-, NOX3-, NOX4- and NOX5-speciﬁc tat-
peptide analogues may become useful pharmaco-
logical tools in the future.
In conclusion, apocynin, AEBSF and DPI appear
to lack speciﬁcity as pharmacological agents when
validating the involvement of NADPH oxidases in
any physiological or pathological function. In con-
trast, triazolo pyrimidines such as VAS3947 are spe-
ciﬁc for NADPH oxidases versus NOS and XOD, and
do not interfere with commonly used ROS assay
systems. However, we cannot exclude the possibility
that VAS3947, in addition to inhibiting NADPH oxi-
dases, also interferes with alternative sources of ROS
that we have not yet investigated, such as the mito-
chondrial electron chain. Future studies will be
required to clarify the precise mechanism of action
and in vivo efﬁcacy of triazolo pyrimidines, and –
once several derivatives become available – their
isoform selectivity. For in vivo experiments, deriva-
tives with higher solubility are essential. Impor-
tantly, by applying VAS3947 to the SHR model, we
here have provided validated pharmacological evi-
dence that NADPH oxidases are a relevant source of
ROS in hypertension.
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